logo

  • Press Releases
  • Events & Presentations
  • Stock Quote & Chart
  • Historical Price Lookup
  • Investment Calculator
  • SEC Filings
  • Annual Reports & AGMs
  • Quarterly Results
  • Documents & Charters
  • Leadership Team
  • Committee Composition
  • PFIC Statement
  • Investor FAQs
  • Investor Contact
  • Email Alerts

Press Release Details

Sophia genetics unveils strategy to drive health care innovations at inaugural investor day event.

Highlights include: a memorandum of understanding with Memorial Sloan Kettering Cancer Center and a novel new partnership with Boundless Bio, a next-generation precision oncology company

SOPHiA GENETICS’ next-generation solution CarePath, fueled by current real world observational data, was previewed for attendees

BOSTON and GENEVA, Switzerland, Sept. 21, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, hosted its first-ever Investor Day on Tuesday, September 20, 2022, in New York City.

The event, hosted by the CEO and Co-Founder Dr. Jurgi Camblong and members of the executive leadership team, provided a roadmap of the Company’s long-term vision and highlighted new commercial opportunities and partnerships. One takeaway from the event was SOPHiA GENETICS’ acceleration into the Biopharma space, which opens the door for new opportunities for market growth. The audience also heard how the Company’s strategic business model allows for it to continue to provide robust depth in the clinical space.

“A key theme throughout the day was how we innovate; how SOPHiA GENETICS, from its inception, has identified opportunities in the healthcare industry for innovation and acceleration of data sharing to advance medicine, research and patient care,” said Jurgi Camblong, CEO and Co-Founder, SOPHiA GENETICS. “Our vision is made possible by the strong foundation our company has been built on, as well as the strategic relationships we have formed to further our mission of democratizing data-driven medicine.”

New Collaboration with One of the Top-Ranked Cancer Centers in the United States SOPHiA GENETICS recently announced a memorandum of understanding to enter into a collaboration with Memorial Sloan Kettering Cancer Center (“MSK”). Once executed, the collaboration agreements will blend the power of SOPHiA GENETICS’ large, global network and deep expertise in predictive algorithms with MSK’s clinical expertise in cancer genomics. The collaboration agreements will also allow SOPHiA GENETICS’ global network of healthcare providers access to MSK’s proprietary tumor sequencing tests such as MSK-IMPACT ® , for analyzing tumors. Additionally, the collaboration agreements will combine MSK’s rich precision oncology data with the SOPHiA CarePath™ module to enable the acceleration of actionable insights from data to improve patient outcomes.

“Our vision is to expand access to world-class data, including to our current network, which contributes to the collective intelligence of the SOPHiA GENETICS platform,” said Philippe Menu, M.D.-Ph.D., Chief Medical Officer, SOPHiA GENETICS.

Enabling Biotech Developing Novel Cancer Therapies Targeting Oncogene Amplification SOPHiA GENETICS announced a partnership with Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers.

It has been well established that patients with oncogene amplification generally do not benefit from standard of care cancer treatments, and unlike other forms of oncogenic gene alterations, oncogene amplification frequently occurs on ecDNA. ecDNA are circular units of nuclear DNA that are distinct from normal chromosomes and are the primary site for high copy number amplification in cancer. Boundless Bio is developing the first ecDNA-directed therapies (ecDTx) along with a precision diagnostic method called ECHO (ecDNA Harboring Oncogenes) to detect ecDNA from a patient’s routine tumor sequencing data.

The partnership between Boundless Bio and SOPHiA GENETICS will further develop ECHO for use in ecDTx clinical trials.

SOPHiA GENETICS’ unique ability to harmonize data derived from diverse genomic instruments and deploy as a robust, standardized solution enables a new model for clinical trial testing. This decentralized, global genomic solution combined with Boundless Bio’s ecDTx drug development capabilities aims to unlock value by breaking the barriers inherent to the traditional central lab approach; optimizing patient selection and clinical trial design; and enabling a global collective network of major hospitals and academic centers to effectively deliver new treatment options to patients with oncogene amplified cancers.

“We are pleased to partner with SOPHiA GENETICS for the development of Boundless Bio’s ecDNA detection algorithm, ECHO, into a clinical trial device,” said Peter Krein, Ph.D., Vice President of Precision Medicine at Boundless Bio. “The ability to identify patients with ecDNA driven tumors is critical to our mission in addressing this area of high unmet medical need. SOPHiA GENETICS’ unique expertise in developing cloud based IVD NGS software algorithms makes them an ideal partner to develop ECHO into an investigational device.”

DEEP-Lung-IV Multimodal Clinical Study Fuels New SOPHiA Carepath Platform In late 2021, SOPHiA GENETICS launched a DEEP-Lung-IV Multimodal Clinical Study with the goal of aggregating real-world multimodal (genomic, clinical, biological and radiomic) data for patients with metastatic non-small cell lung cancer. The study has garnered interest from top-tier centers globally, with a strong patient recruitment trend; to-date, nearly 900 patients across 23 sites have been enrolled in the study. As patients have been followed along the patient journey, data sets have been collected and analyzed by SOPHiA GENETICS’ machine learning algorithm to predict how the patients will respond to immunotherapy and why.

These robust and growing patient data will inform SOPHiA GENETICS’ artificial intelligence and machine learning that will fuel the forthcoming SOPHiA CarePath™ module, a new product that will be launched on the SOPHiA DDM™ Platform and aims to be the vehicle healthcare practitioners can use to leverage the real-world, real-time insights obtained from this study. The SOPHiA CarePath™ module will provide the following benefits:

  • Visualizing data form a single patient in a holistic manner (genomic, clinical, biological and radiomic)
  • Allow providers to cohort patients in the context of similar patients from other institutions

Alongside these announcements, a full recording of the event is available on the  Investor Relations  page of the company’s website.

About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit  SOPHiAGENETICS.COM , or connect on  Twitter ,  LinkedIn , Facebook , and  Instagram .  Where others see data, we see answers

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements: This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact: Kelly Katapodis Senior Manager, Media & Communications [email protected]

Investor Contact: Jennifer Pottage Head of Investor Relations [email protected]

sophia genetics case study

  • S&P Dow Jones Indices
  • S&P Global Market Intelligence
  • S&P Global Mobility
  • S&P Global Commodity Insights
  • S&P Global Ratings
  • S&P Global Sustainable1
  • Investor Relations Overview
  • Investor Presentations
  • Investor Fact Book
  • News Releases
  • Quarterly Earnings
  • SEC Filings & Reports
  • Executive Committee
  • Corporate Governance
  • Merger Information
  • Stock & Dividends
  • Shareholder Services
  • Contact Investor Relations
  • Email Subscription Center
  • Media Center

S&P Global Market Intelligence

SOPHiA Genetics to use $110M funding to expand data offering, prepare for IPO

Banking Essentials: January 10th

A Bank Outsources Data Gathering to Meet Basel III Regulations

The New SEC Private Fund Adviser Rules: Understanding the Basics

2023 Year in Review Key Capital Markets Trends

  • 1 Oct, 2020
  • Author Morgan Frey

SOPHiA Genetics SA raised $110 million in a Series F round, furthering the company's ambitions to become a leader in data-driven medicine across multiple disease states.

The Saint-Sulpice, Switzerland-based health technology company's latest funding round was led by Israeli venture fund aMoon Fund and Hitachi Ventures Fund, the venture capitalist arm of Japanese company Hitachi Ltd. In addition to SOPHiA, aMoon has also invested in other health tech and life sciences companies such as Karius Inc. and MiNA Therapeutics Ltd.

Other participants in the round included Credit Suisse Group AG and the Pictet Group, existing investors are Swisscom Ventures, Endeavour Vision SA, Generation Investment Management LLP, Alychlo NV and EuraZeo Growth, and new investors include ACE & Co. and Famille C Invest.

SOPHiA's genomics platform is used by hospitals and cancer centers to analyze patients' genomic profiles to allow providers to detect cancer or certain hereditary disorders. The company helps over 1,000 hospitals worldwide and 102 hospitals in the U.S. compute 17,000 genomic profiles each month, according to CEO Jurgi Camblong.

The company has also added radiomics capabilities for analyzing medical images and a clinical trial platform that matches patients to clinical trials.

SOPHiA's previous funding round, in January 2019, netted the company an additional $77 million in funding, which included secondary transactions such as share purchases, Camblong said. However, this latest funding round, which nearly doubled its total funding of about $139 million, is just cash.

Camblong credits the fast growth to the company's entry into the North American market and to partnerships in the biopharmaceutical industry.

"I think these two things, which are now the core of our strategy for the next few years — the U.S. penetration, the biopharma potential — have really demonstrated that SOPHiA was in a unique position versus many others and has attracted substantial amount of capital," Camblong told S&P Global Market Intelligence.

Alongside this core strategy, Camblong said SOPHiA plans to use the money to add additional capabilities to its genomics platform and expand the radiomics capabilities. By providing hospitals with additional data capabilities, the company can in turn help the biopharma industry find the best patients for clinical trials.

"Now we are in a stage where we can add these additional modalities of data because we have proven with some proof of concepts that combining imaging data with molecular data [really] makes a difference in terms of guessing which treatment will be the best-suited for a specific patient suffering from cancer," Camblong said.

In addition to the funding round, the company also announced it has added Didier Hirsch, former CFO at Agilent Technologies Inc., to SOPHiA's board. This is not the first personnel change for the company in 2020: Troy Cox was elected chairman of the board in February, Philippe Menu was appointed chief medical officer and Lara Hashimoto was named chief business officer.

Each of these hires, along with the strong funding, is helping the company prepare for an IPO in the next two or three years, according to Camblong. The ultimate goal is to go public in the U.S. on the Nasdaq, and some of the money from this Series F round will go toward helping the company expand into U.S. and Asian markets.

According to Camblong, going public in the U.S. will help the company make more deals with hospitals and biopharma companies and build trust with the public at large.

"I think trust is very important in our space, but as well [SOPHiA would be able] to attract talents and get access to cash, to do acquisitions, to execute acquisition opportunities and, again, expand the network and add new modalities of data capabilities in our platform," Camblong said.

When considering what other modalities could possibly be added to SOPHiA's technology, Camblong points to the company's quick addition of infectious diseases with the onset of COVID-19. By the end of the year, the company will have helped decipher the genome content of 18,000 viruses worldwide, Camblong said, which will help it track viruses like COVID-19 even as they mutate years from now.

" I think this is a nice example of how one can leverage on our dominant platform position with this network of thousands [of] hospitals," Camblong said, "because now we can imagine that [in a] few months or years down the road, SOPHiA will be in an exceptional position to know how the virus evolved in terms of geography, in terms of time, as well as in terms of its genomic dimension."

  • Morgan Frey

Case Study - Genomic Diagnostics, Australia

Genomic Diagnostics improve equity of access to genomic analysis in Australia with the SOPHiA DDM™ Hereditary Cancer Solution v1.1. Watch Mark Williams, Chief Scientist at Genomic Diagnostics explain how implementing the SOPHiA DDM™️ NGS workflow enabled the laboratory to provide affordable and quality genomic analysis.

sophia genetics case study

Want to learn more?

One of our experts will be in touch with you shortly!

Institution

Country United States Canada Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Croatia Cuba Curaçao Cyprus Czech Republic Côte d’Ivoire Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong S.A.R., China Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao S.A.R., China Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Romania Russia Rwanda Réunion Saint Barthélemy Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu U.S. Virgin Islands Uganda Ukraine United Arab Emirates United Kingdom United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Vatican Venezuela Viet Nam Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe

Privacy Policy I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. View our Privacy Policy for more information.

Pardot Opt-in I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able to unsubscribe by using the link integrated with the communication at any time.

Cookie Notice

This site uses cookies for performance, analytics, personalization and advertising purposes.

For more information about how we use cookies please see our Cookie Policy .

Cookie Policy   |   Privacy Policy

Manage Consent Preferences

Essential/Strictly Necessary Cookies

These cookies are essential in order to enable you to move around the website and use its features, such as accessing secure areas of the website.

Analytical/ Performance Cookies

These are analytics cookies that allow us to collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. This helps us to improve the way the website works and allows us to test different ideas on the site.

Functional/ Preference Cookies

These cookies allow our website to properly function and in particular will allow you to use its more personal features.

Targeting/ Advertising Cookies

These cookies are used by third parties to build a profile of your interests and show you relevant adverts on other sites. You should check the relevant third party website for more information and how to opt out, as described below.

sophia genetics case study

  • Starburst vs OSS Trino

By Use Cases

  • Modern Data Lake
  • Artificial Intelligence
  • ELT Data Processing
  • Data Applications
  • Data Migrations

By Industry

  • Financial Services
  • Healthcare & Life Sciences
  • Retail & CPG
  • All Industries
  • Meet our Customers
  • Customer Experience
  • Starburst Data Rebels
  • Data Fundamentals
  • Upcoming Events
  • Documentation
  • Starburst Academy
  • Become a Partner
  • Partner Login
  • Security & Trust

sophia genetics case study

Starburst Galaxy

Fully managed in the cloud

  • Starburst Enterprise

Self-managed anywhere

sophia genetics case study

Querying across borders to advance data-driven medicine

Sophia genetics deploys starburst to query across borders and accelerate their data mesh initiative..

access point to global data

increase in users accessing production data

greater data availability

Healthcare & Life Science

sophia genetics case study

One of the core missions of my team is to make the data mesh happen while still maintaining everything that we need to maintain in terms of policies and data privacy constraints. Starburst is making my life a lot easier by creating the first mesh platform for business metrics, that we can start operating within.

Alexander Seeholzer

Director, Data Services

SOPHiA GENETICS is advancing and democratizing data-driven medicine through a pioneering global network of healthcare institutions. Working with more than 780 hospitals and research institutions in over 70 countries, SOPHiA GENETICS enables its customers to outsource their bioinformatics operations by providing them with both a cloud-based, Software-as-a-Service analytics platform and unprecedented insights from the global network. This way, SOPHiA GENETICS’ customers can focus on what they do best — advancing research, treatment decisions, and drug development efforts.    

Challenge: 

Over the years, SOPHiA GENETICS has come to rely on a mix of different backend storage systems. Cataloging data and collecting business metrics were becoming increasingly difficult, since application data is distributed globally to comply with various regional and national data security and compliance requirements. Ultimately, the data services team wanted to be able to catalog its data and allow creating business insights in a secure, controllable, and demonstrably compliant way.

Starburst Enterprise, the fully supported, production-tested distribution of open source Trino, improves performance while making it easy to deploy, connect, and manage your cluster. It includes additional connectors for commercial database systems along with query optimization, cluster management tools, and enhanced security – an especially important feature to SOPHiA GENETICS.

“Starburst is creating the infrastructure to realize our business metrics demands, while tightly controlling access to source systems,” Alexander Seeholzer, Director, Data Services at SOPHiA GENETICS explains, “and it offers enterprise-grade extensions, auditability, and more at an affordable price. After our evaluation, we realized it was the most logical choice.”

Today, the data SOPHiA GENETICS manages resides in data warehouses within specific regions or countries. SOPHiA GENETICS deploys Starburst via Kubernetes and operates numerous instances, including in-country or in-region clusters that ensure compliance with local data regulations. 

Key features:

Fine-grained access control:

  • Managing data consumers and gathering insights into their activity has improved significantly. “We basically have one entry point that we can use to serve access to different users and automated systems, whereas before, access had to be done on a per-resource basis. It was a service overhead to maintain that,” notes Seeholzer. “Starburst allows us to specify on a per user basis, in a very fine-grained manner, who is allowed access to what, and it gives us an auditable trail of that activity.”

Regional compliance:

  • SOPHiA GENETICS adheres to strict requirements to secure data within specific regions or countries, as regulations demand. “Due to compliance constraints, we simply can not deploy any system that accesses all data from one central point,” Seeholzer says. “One advantage of Starburst is that we can deploy Starburst distributed too, in each region, and make it so the source data used to generate business metrics never leaves the region.”

Exploration & discovery:

  • Starburst has also made it easier for  SOPHIA’s data services team to explore and catalog data. In the past, this would have been done semi-automatically, but now the process can be fully automated. The team can easily build, maintain, and update catalogs of data across different storage systems, which in turn makes discovery much easier.

Starburst Stargate

  • SOPHiA GENETICS relies on Starburst Stargate, a cluster-to-cluster connector, designed to analyze distributed data while remaining compliant. “We don’t have one Starburst cluster that queries everything,” explains Seeholzer. “We have Starburst clusters everywhere, and another Starburst-to-Starburst connector that queries all clusters, in a secure and compliant fashion.” Starburst’s optimizer reduces the amount of data transferred over the network by executing aggregation operations in source systems when possible. This allows the team to collect the necessary business metrics.

SOPHiA GENETICS sees various strategic and operational advantages of the solution.

10-15X more data available

By unlocking siloed data, SOPHiA GENETICS has 10-15X more data available that is leveraged to improve their product offering. Additionally, the company expanded the number of users able to query data from 3 to 30, a 900% increase in data access . 

Centralized data access 

Data activities that had been dispersed are now accessed through a single point of secure access, making them more controllable and observable. 

With Starburst, it’s easier for the data services team to demonstrate to auditors, the QA department, and others that they are adhering to policies and regulations.

Time-to-insight 

Business analysts can explore data faster because the datasets, columns, and rows they’re permitted to access have already been established, and they don’t need to appeal to data services. This cuts down on the turnaround time and, ultimately, accelerates time-to-insight.

Accelerating the data mesh initiative As SOPHiA GENETICS advances its mission, Starburst Enterprise will continue to be an important piece of its infrastructure. In addition to the benefits outlined above, the platform is advancing one of the larger strategic goals of the data services team – moving toward the increasingly popular data mesh architecture now being adopted by many forward-thinking enterprises.

More resources: Alexander Seeholzer’s Voyager profile

Assurance Case Study

Food & beverage giant, banco inter case study, novant health, fortune 100 cloud computing provider case study, a single point of access to all your data, stay in the know - sign up for our newsletter.

  • Resource Library
  • Events and Webinars
  • Open-source Trino

Quick Links

Get in touch.

  • Customer Support
  • Trino Community Forum

LinkedIn

© Starburst Data, Inc. Starburst and Starburst Data are registered trademarks of Starburst Data, Inc. All rights reserved. Presto®, the Presto logo, Delta Lake, and the Delta Lake logo are trademarks of LF Projects, LLC

Read Starburst reviews on G2

Privacy Policy   |   Legal Terms   |   Cookie Notice

Start Free with Starburst Galaxy

Up to $500 in usage credits included

  • Query your data lake fast with Starburst's best-in-class MPP SQL query engine
  • Get up and running in less than 5 minutes

For more deployment options:

Please fill in all required fields and ensure you are using a valid email address.

By clicking Create Account , you agree to Starburst Galaxy's terms of service and privacy policy .

SOPHiA GENETICS Unveils Strategy to Drive Health Care Innovations at Inaugural Investor Day Event

September 21, 2022 07:02 ET | Source: SOPHiA GENETICS, Inc. SOPHiA GENETICS, Inc.

Highlights include: a memorandum of understanding with Memorial Sloan Kettering Cancer Center and a novel new partnership with Boundless Bio, a next-generation precision oncology company

SOPHiA GENETICS’ next-generation solution CarePath, fueled by current real world observational data, was previewed for attendees

BOSTON and GENEVA, Switzerland, Sept. 21, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, hosted its first-ever Investor Day on Tuesday, September 20, 2022, in New York City.

The event, hosted by the CEO and Co-Founder Dr. Jurgi Camblong and members of the executive leadership team, provided a roadmap of the Company’s long-term vision and highlighted new commercial opportunities and partnerships. One takeaway from the event was SOPHiA GENETICS’ acceleration into the Biopharma space, which opens the door for new opportunities for market growth. The audience also heard how the Company’s strategic business model allows for it to continue to provide robust depth in the clinical space.

“A key theme throughout the day was how we innovate; how SOPHiA GENETICS, from its inception, has identified opportunities in the healthcare industry for innovation and acceleration of data sharing to advance medicine, research and patient care,” said Jurgi Camblong, CEO and Co-Founder, SOPHiA GENETICS. “Our vision is made possible by the strong foundation our company has been built on, as well as the strategic relationships we have formed to further our mission of democratizing data-driven medicine.”

New Collaboration with One of the Top-Ranked Cancer Centers in the United States SOPHiA GENETICS recently announced a memorandum of understanding to enter into a collaboration with Memorial Sloan Kettering Cancer Center (“MSK”). Once executed, the collaboration agreements will blend the power of SOPHiA GENETICS’ large, global network and deep expertise in predictive algorithms with MSK’s clinical expertise in cancer genomics. The collaboration agreements will also allow SOPHiA GENETICS’ global network of healthcare providers access to MSK’s proprietary tumor sequencing tests such as MSK-IMPACT ® , for analyzing tumors. Additionally, the collaboration agreements will combine MSK’s rich precision oncology data with the SOPHiA CarePath™ module to enable the acceleration of actionable insights from data to improve patient outcomes.

“Our vision is to expand access to world-class data, including to our current network, which contributes to the collective intelligence of the SOPHiA GENETICS platform,” said Philippe Menu, M.D.-Ph.D., Chief Medical Officer, SOPHiA GENETICS.

Enabling Biotech Developing Novel Cancer Therapies Targeting Oncogene Amplification SOPHiA GENETICS announced a partnership with Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers.

It has been well established that patients with oncogene amplification generally do not benefit from standard of care cancer treatments, and unlike other forms of oncogenic gene alterations, oncogene amplification frequently occurs on ecDNA. ecDNA are circular units of nuclear DNA that are distinct from normal chromosomes and are the primary site for high copy number amplification in cancer. Boundless Bio is developing the first ecDNA-directed therapies (ecDTx) along with a precision diagnostic method called ECHO (ecDNA Harboring Oncogenes) to detect ecDNA from a patient’s routine tumor sequencing data.

The partnership between Boundless Bio and SOPHiA GENETICS will further develop ECHO for use in ecDTx clinical trials.

SOPHiA GENETICS’ unique ability to harmonize data derived from diverse genomic instruments and deploy as a robust, standardized solution enables a new model for clinical trial testing. This decentralized, global genomic solution combined with Boundless Bio’s ecDTx drug development capabilities aims to unlock value by breaking the barriers inherent to the traditional central lab approach; optimizing patient selection and clinical trial design; and enabling a global collective network of major hospitals and academic centers to effectively deliver new treatment options to patients with oncogene amplified cancers.

“We are pleased to partner with SOPHiA GENETICS for the development of Boundless Bio’s ecDNA detection algorithm, ECHO, into a clinical trial device,” said Peter Krein, Ph.D., Vice President of Precision Medicine at Boundless Bio. “The ability to identify patients with ecDNA driven tumors is critical to our mission in addressing this area of high unmet medical need. SOPHiA GENETICS’ unique expertise in developing cloud based IVD NGS software algorithms makes them an ideal partner to develop ECHO into an investigational device.”

DEEP-Lung-IV Multimodal Clinical Study Fuels New SOPHiA Carepath Platform In late 2021, SOPHiA GENETICS launched a DEEP-Lung-IV Multimodal Clinical Study with the goal of aggregating real-world multimodal (genomic, clinical, biological and radiomic) data for patients with metastatic non-small cell lung cancer. The study has garnered interest from top-tier centers globally, with a strong patient recruitment trend; to-date, nearly 900 patients across 23 sites have been enrolled in the study. As patients have been followed along the patient journey, data sets have been collected and analyzed by SOPHiA GENETICS’ machine learning algorithm to predict how the patients will respond to immunotherapy and why.

These robust and growing patient data will inform SOPHiA GENETICS’ artificial intelligence and machine learning that will fuel the forthcoming SOPHiA CarePath™ module, a new product that will be launched on the SOPHiA DDM™ Platform and aims to be the vehicle healthcare practitioners can use to leverage the real-world, real-time insights obtained from this study. The SOPHiA CarePath™ module will provide the following benefits:

  • Visualizing data form a single patient in a holistic manner (genomic, clinical, biological and radiomic)
  • Allow providers to cohort patients in the context of similar patients from other institutions

Alongside these announcements, a full recording of the event is available on the  Investor Relations  page of the company’s website.

About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit  SOPHiAGENETICS.COM , or connect on  Twitter ,  LinkedIn , Facebook , and  Instagram .  Where others see data, we see answers

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements: This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact: Kelly Katapodis Senior Manager, Media & Communications [email protected]

Investor Contact: Jennifer Pottage Head of Investor Relations [email protected]

sophia genetics case study

SOPHiA GENETICS

Partner with us

pink dots icon

Our partnering areas of interest

In our vision of data-driven medicine, robust disease characterization through aggregated, multimodal data enables personalized care throughout an individual’s treatment journey. For instance, in oncology we aim to assess tumor evolution by combining tumor profiling at the molecular level with longitudinal follow-up using radiomic, pathology, laboratory, and clinical data.

Each institution within the SOPHiA GENETICS community gains knowledge and insights to improve their expertise in treating disease. Therefore, the aggregated insights from anonymized data across institutions create a collective intelligence on multiple disorders. This further supports confident, informed decision-making and can accelerate the discovery and improvement of targeted therapeutics.

To fully leverage this potential requires a decentralized approach enabling any permissioned user to produce and share data and derive insights through a secure cloud platform.

sophia genetics case study

Why partner with us?

Our featured partners.

sophia genetics case study

“The integration of genomics-based artificial intelligence into oncology workflow solutions would be a major breakthrough for integrated cancer medicine and for future clinical research, which increasingly depend on the ability to select those patients most likely to respond to new therapies,” said Jan Makela, President & CEO, Imaging at GE Healthcare. ”This collaboration [with SOPHiA GENETICS] represents another step in GE Healthcare’s vision of making precision health — more efficient and personalized care — a reality.”

Jan Makela, President & CEO – GE Healthcare

“SOPHiA GENETICS is a leader in precision medicine,” said Keiji Kojima, Executive Vice President and Executive Officer, and General Manager of Smart Life Business Management Division of Hitachi, Ltd. “Hitachi is excited to start long term partnership with SOPHiA GENETICS to co-create innovative solutions for improving Quality of Life of patients by leveraging both companies’ data analytics and AI technologies.”

Keiji Kojima, Executive Vice President, Executive Officer, & General Manager of Smart Life Business Management Division – Hitachi

This information is as of the date of the press announcement on March 25, 2021.

“These remarkable partners have displayed a deep commitment to building world-class solutions for customers — from cloud-to-edge — and represent some of the best and brightest our ecosystem has to offer,” said Rodney Clark, Corporate Vice President of Global Partner Solutions in Channel Sales and Channel Chief at Microsoft.

“Genomics research is enabling a shift from a broad-based one-size-fits-all approach to a personalized experience. Pairing our industry-leading, rapidly customizable enrichment efficiency with SOPHiA GENETICS robust analytical platform provides customers an important solution to achieve clinically actionable data while saving on sequencing costs. We are excited to work with SOPHiA GENETICS to provide this new combined offering to clinical researchers around the world.”

Emily M. Leproust, Ph.D., CEO and Co-founder – Twist Bioscience

Ready to discuss a potential partnering opportunity?

IMAGES

  1. Sophia Genetics

    sophia genetics case study

  2. Case Study: SOPHiA GENETICS

    sophia genetics case study

  3. Case Stusy 2 Sophia Genetics COMPLETED.docx

    sophia genetics case study

  4. Capabilities

    sophia genetics case study

  5. Sophia Genetics Case Study.docx

    sophia genetics case study

  6. New Data Presented at ESGO Showcases Clinical Relevance of SOPHiA DDM

    sophia genetics case study

VIDEO

  1. Pancreatic Cancer Screening

  2. The Strange Case of Sophia's Daughter

  3. Genetics problems in Extended Family Marriages🤯

  4. My Study Abroad Experience at Sophia University

  5. MLA Genetics Case Study Series 2

COMMENTS

  1. Case Studies

    Case Studies - SOPHiA GENETICS Case Studies Real-world examples of what's possible, together Genomic Diagnostics, Australia Genomic Diagnostics improve equity of access to hereditary cancer genomic analysis in Australia with the SOPHiA DDM™ Hereditary Cancer Solution v1.1. VIEW CASE STUDY TomaLab Advanced Biomedical Assays

  2. SOPHiA GENETICS Unveils Strategy to Drive Health Care Innovations at

    In late 2021, SOPHiA GENETICS launched a DEEP-Lung-IV Multimodal Clinical Study with the goal of aggregating real-world multimodal (genomic, clinical, biological and radiomic) data for patients with metastatic non-small cell lung cancer. The study has garnered interest from top-tier centers globally, with a strong patient recruitment trend; to ...

  3. Case Study: SOPHiA GENETICS

    Case Study: SOPHiA GENETICS Starburst 2.16K subscribers Subscribe Subscribed 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 Share 375 views 1 year ago SOPHiA GENETICS deploys...

  4. PDF SOPHiA GENETICS Deploys Starburst to Tighten Access Controls and

    SOPHiA GENETICS is advancing and democratizing data-driven medicine through a pioneering global network of healthcare institutions.

  5. SOPHiA GENETICS on LinkedIn: Clinical Case Study: SOPHiA DDM™ Dx

    1mo Report this post How does the SOPHiA DDM™ Platform enable clinical researchers improve outcomes for ovarian cancer patients? Read our latest clinical case study and explore how TomaLab...

  6. SOPHiA GENETICS on LinkedIn: Access the case study on a customized

    SOPHiA GENETICS' Post SOPHiA GENETICS 99,581 followers 11mo Report this post It is that easy to set up a custom panel for your sequencing needs! ... READ the case study HERE: ...

  7. Sophia Genetics

    $250m raised from VC 500+ staff, internationally New Deep Learning Capabilities to Support the Detection of Homologous Recombination Deficiencies (Video - 01:50) Key achievements Over 790 healthcare institution customers in more than 70 countries 1m+ genomic profiles analysed

  8. SOPHiA Genetics to use $110M funding to expand data offering, prepare

    SOPHiA Genetics SA raised $110 million in a Series F round, furthering the company's ambitions to become a leader in data-driven medicine across multiple disease states.

  9. Case Study

    Genomic Diagnostics improve equity of access to genomic analysis in Australia with the SOPHiA DDM™ Hereditary Cancer Solution v1.1. Watch Mark Williams, Chief Scientist at Genomic Diagnostics explain how implementing the SOPHiA DDM™️ NGS workflow enabled the laboratory to provide affordable and quality genomic analysis. Want to learn more?

  10. SOPHiA GENETICS on LinkedIn: Access the case study on a customized

    SOPHiA GENETICS' Post SOPHiA GENETICS 91,055 followers 2mo Report this post ...

  11. SOPHiA GENETICS

    1 access point to global data 900% increase in users accessing production data 10-15% greater data availability About: SOPHiA GENETICS is advancing and democratizing data-driven medicine through a pioneering global network of healthcare institutions.

  12. SOPHiA GENETICS

    750+ Healthcare Institutions OUR GLOBAL FOOTPRINT 70+ Countries GENOMIC PROFILES 1.2 Million+ Genomic Profiles Analyzed Retain ownership of your data. SOPHiA DDM™: A universal healthcare analytics platform

  13. SOPHiA GENETICS Unveils Strategy to Drive Health Care

    In late 2021, SOPHiA GENETICS launched a DEEP-Lung-IV Multimodal Clinical Study with the goal of aggregating real-world multimodal (genomic, clinical, biological and radiomic) data for patients ...

  14. SOPHiA GENETICS on LinkedIn: Access the case study on a customized

    SOPHiA GENETICS 87,716 followers 2d Report this post Report Report. Back ...

  15. 3 SOPHiA GENETICS Case Studies, Success Stories, & Customer Stories

    SOPHiA GENETICS Case Studies. Browse SOPHiA GENETICS case studies and success stories to help make the right purchasing decision. 1-3 of 3 results. Indian research hospital chose SOPHiA DDM™ for the analysis of gene fusion events.

  16. SOPHiA GENETICS

    Read the case study and watch the video: https://ter.li/jbroem #HereditaryCancer #Oncology #Genomics #NGS #DataDrivenMedicine. ... SOPHiA GENETICS is the creator of SOPHiA DDM™, a cloud-based ...

  17. Sophia Genetics Case Study.docx

    Sophia Genetics Case Study.docx - Sophia Genetics Moves precision Medicine Ahead What advantages does the Sophia DDM system have compared to the | Course Hero Sophia Genetics Case Study.docx - Sophia Genetics Moves... Doc Preview Pages 1 Identified Q&As 3 Solutions available Total views 100+ Murang'a Institute of Technology - Murang'a BUSINESS S

  18. SOPHiA GENETICS on LinkedIn: Case Study

    Familial variant analysis with the SOPHiA DDM™️ Platform can identify inherited variants from clinical exome data. Learn more in our case study HERE: https://ter.li/r2gbq6 #Variant #Exome # ...

  19. SOPHiA GENETICS Partners with Microsoft to Accelerate Multimodal Health

    Geneva, Switzerland - November 1, 2022 - SOPHiA GENETICS™ (Nasdaq: SOPH), a cloud-native software company in the healthcare space, is embarking on a multi-year integrated strategic partnership with Microsoft to improve healthcare workflows globally.

  20. Partnering

    SOPHiA GENETICS has specific interest in oncology, rare disease, cardiology, neurology, and metabolism. Why partner with us? At SOPHiA GENETICS, we believe in the power of collaboration.